한글목차

전립선암 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 195억 1,000만 달러에서 2026년에는 205억 4,000만 달러에 이르고, CAGR 5.3%로 성장할 전망입니다. 지난 몇 년간 성장 요인으로는 남성 인구의 고령화, 전립선암 검진 보급, 호르몬 요법의 광범위한 채택, 종양 전문 클리닉 증가, 암에 대한 인식 증가 등을 꼽을 수 있습니다.

전립선암 치료제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 261억 5,000만 달러에 이르고, CAGR은 6.2%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 표적치료제 및 면역치료제 확대, 진행성 전립선암 환자 증가, 치료의 개인화 발전, 의료 접근성 확대, 암 치료비 증가 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 조기 치료에서 호르몬 요법의 사용 증가, 표적 전립선암 치료제의 도입 확대, 거세 저항성 전립선암에 대한 관심 증가, 병용요법 접근법 확대, 병원 기반 전립선암 치료 증가 등을 들 수 있습니다.

고령 남성 인구 증가는 향후 몇 년 동안 전립선암 치료제 시장의 성장을 견인할 것으로 예측됩니다. 고령 남성 인구는 일반적으로 노화에 따른 건강 문제의 유병률이 높고 전문적인 건강관리가 필요한 65세 이상의 남성을 의미합니다. 이러한 고령 남성 인구 증가는 의료 서비스 접근성 향상, 사망률 감소, 전 세계 평균 수명 연장에 기인합니다. 고령 남성 증가는 질병 관리 및 생존율 향상을 위한 호르몬 요법, 면역 요법, 화학 요법, 표적 치료를 필요로 하는 환자 기반을 확대하여 전립선암 치료제 수요를 촉진합니다. 예를 들어, 스위스에 본부를 둔 국제 공중보건기구인 세계보건기구(WHO)는 2025년 2월, 2024년 세계 평균 기대수명이 73.3세에 이르렀으며, 전 세계 60세 이상 인구가 2023년 11억 명에서 2030년까지 14억 명으로 증가할 것으로 예측된다고 보고했습니다. 보고했습니다. 그 결과, 증가하는 고령 남성 인구가 전립선암 시장의 성장을 주도하고 있습니다.

전립선암 치료제 시장에서 사업을 전개하는 주요 기업들은 시장 수익을 극대화하기 위해 신제품 출시 및 연방 기관으로부터의 승인 획득을 위한 노력을 연계하여 진행하고 있습니다. 의약품 개발 및 승인 절차는 장기적이고 복잡하기 때문에 스폰서 기업은 안전성과 유효성을 합리적으로 보장하기 위해 필요한 규제 요건과 판매 경로를 이해하는 것이 매우 중요합니다. 예를 들어, 2023년 6월 영국에 본사를 둔 제약사 아스트라제네카와 미국에 본사를 둔 제약사 머크 앤 컴퍼니는 미국 식품의약국(USFDA)이 LYNPARZA(올라파립)와 압달라빈의 병용요법을 승인했다고 발표했습니다. 미국 식품의약국(USFDA)은 미국 식품의약국(USFDA)이 LYNPARZA(성분명: 올라파립)와 아비라테론 및 프레드니손 또는 프레드니솔론 병용요법을 BRCA 변이가 있는 전이성 거세저항성 전립선암(mCRPC) 성인 환자 치료제로 승인했다고 발표했습니다. mCRPC) 성인 환자 치료제로 승인했다고 발표했습니다. 이번 승인의 근거가 된 3상 PROpel 임상연구의 탐색적 하위그룹 분석에 따르면, LYNPARZA와 아비라테론/프레드니손 또는 프레드니솔론 병용요법은 BRCA 변이 양성 mCRPC 환자에서 아비라테론/프레드니손 단독요법 대비 무진행생존기간(rPFS)과 무진행생존기간(rPFS) 기간(rPFS) 및 전체 생존기간(OS) 모두에서 임상적으로 유의미한 개선을 보였습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Prostate cancer drugs are medications used for the prevention and treatment of prostate cancer. Prostate cancer is a common type of cancer that occurs due to the uncontrolled growth of cells in the prostate gland in men, which produces the seminal fluid that nourishes and transports sperm. Some potential treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy, and targeted therapy.

Prostate cancer drugs can be classified into hormone-sensitive prostate cancer and hormone-refractory prostate cancer. Hormone-refractory prostate cancer (HRPC) is a type of prostate cancer that no longer responds to hormone therapy, including newer treatments. The available therapies include hormonal therapy, chemotherapy, immunotherapy, and targeted therapy and are used across various settings such as hospitals, clinics, and other healthcare facilities.

Tariffs have increased the cost of imported APIs and specialty oncology drugs used in prostate cancer treatment across multiple therapy classes. These impacts are most pronounced in targeted therapy segments and hospital procurement channels, where pricing sensitivity and supply reliability are critical. Regions such as North America and Europe have experienced higher input costs due to reliance on cross border oncology supply chains. Rising tariff related expenses have influenced treatment pricing, reimbursement discussions, and procurement planning in oncology care settings. Conversely, tariffs have encouraged domestic pharmaceutical production, expanded local manufacturing capacity, and improved regional drug availability over the long term.

The prostate cancer drugs market research report is one of a series of new reports from The Business Research Company that provides prostate cancer drugs market statistics, including prostate cancer drugs industry global market size, regional shares, competitors with a prostate cancer drugs market share, detailed prostate cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer drugs industry. This prostate cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer drugs market size has grown strongly in recent years. It will grow from $19.51 billion in 2025 to $20.54 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to aging male population, increased prostate cancer screening, widespread hormone therapy adoption, expansion of oncology clinics, rising cancer awareness.

The prostate cancer drugs market size is expected to see strong growth in the next few years. It will grow to $26.15 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growth in targeted and immunotherapy drugs, rising incidence of advanced prostate cancer, increasing treatment personalization, expanding healthcare access, growth in oncology spending. Major trends in the forecast period include rising use of hormonal therapy in early treatment, increased adoption of targeted prostate cancer drugs, growing focus on castration-resistant prostate cancer, expansion of combination therapy approaches, increased hospital-based prostate cancer care.

The growing male geriatric population is anticipated to drive the expansion of the prostate cancer drugs market in the coming years. The male geriatric population refers to men aged 65 and above, who generally face a higher prevalence of age-related health conditions and require specialized medical care. This increase in the aging male population is attributed to better access to healthcare, declining mortality rates, and longer life expectancies globally. The rising number of elderly men fuels demand for prostate cancer drugs by increasing the patient base in need of hormonal therapies, immunotherapies, chemotherapy, and targeted treatments for disease management and improved survival. For example, in February 2025, the World Health Organization, a Switzerland-based international public health organization, reported that global life expectancy at birth reached 73.3 years in 2024, and the number of people aged 60 and above worldwide is expected to grow from 1.1 billion in 2023 to 1.4 billion by 2030. Consequently, the increasing male geriatric population is driving the growth of the prostate cancer market.

Major companies operating in the prostate cancer drugs market coordinate their efforts in launching new products and securing approvals from federal agencies to maximize market revenues. The drug development and approval process is lengthy and complex, making it crucial for drug sponsors to understand the regulatory requirements and marketing pathways necessary to ensure reasonable assurance of safety and effectiveness. For example, in June 2023, AstraZeneca PLC, a UK-based pharmaceutical company, and Merck & Co. Inc., a US-based pharmaceutical company, announced that the United States Food and Drug Administration (USFDA), a federal agency under the US Department of Health and Human Services, approved LYNPARZA (olaparib) in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). LYNPARZA plus abi/pred showed clinically significant improvements in both radiographic progression-free survival (rPFS) and overall survival (OS) compared to abi/pred alone in patients with BRCAm mCRPC, according to an exploratory subgroup analysis of the Phase 3 PROpel trial, which formed the basis for this approval.

In March 2024, Johnson & Johnson, a US-based pharmaceutical industry company, acquired Ambrx Biopharma Inc. for an undisclosed amount. Through this acquisition, Johnson & Johnson aims to develop targeted oncology therapeutics using Ambrx's proprietary ADC technology, which combines highly specific monoclonal antibodies with potent chemotherapeutic agents. This approach enhances the precision of cancer treatments, minimizing common chemotherapy side effects and transforming the treatment landscape for solid tumors, including prostate cancer. Ambrx Biopharma Inc. is a US-based biotechnology company specializing in the development of innovative therapies, including prostate cancer drugs.

Major companies operating in the prostate cancer drugs market are Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Exelixis Inc.

North America was the largest region in the prostate cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the prostate cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The prostate cancer drugs market consists of sales of Abiraterone Acetate, Apalutamide, and Bicalutamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Prostate Cancer Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses prostate cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for prostate cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The prostate cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Hormone Sensitive Prostate Cancer; Hormone Refractory Prostate Cancer
• 2) By Therapy: Hormonal Therapy; Chemotherapy; Immunotherapy; Targeted Therapy
• 3) By End User: Hospitals; Clinics; Other End-Users
• Subsegments:
• 1) By Hormone Sensitive Prostate Cancer: Early-Stage Prostate Cancer; Locally Advanced Prostate Cancer; Metastatic Prostate Cancer
• 2) By Hormone Refractory Prostate Cancer: Castration-Resistant Prostate Cancer (CRPC); Metastatic Castration-Resistant Prostate Cancer (mCRPC)
• Companies Mentioned: Astellas Pharma Inc.; AstraZeneca PLC; Johnson & Johnson; Sanofi S.A.; Bayer AG; Abbott Laboratories; Pfizer Inc.; Novartis International AG; F. Hoffmann-La Roche Ltd.; Tolmar Inc.; AbbVie Inc.; Siemens Healthineers AG; Genomic Health Inc.; OPKO Health Inc.; Siemens Healthcare GmbH; MDxHealth SA; Myriad Genetics Inc.; Janssen Biotech Inc.; Clovis Oncology Inc.; Merck Sharp & Dohme Corp.; Dendreon Corporation; Ferring Pharmaceuticals Inc.; Ipsen Biopharmaceuticals Inc.; Merck & Co. Inc.; Eli Lilly and Company Inc.; Bristol-Myers Squibb Company; Takeda Pharmaceutical Company Limited; Novartis AG; Amgen Inc.; Regeneron Pharmaceuticals Inc.; Exelixis Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Prostate Cancer Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Prostate Cancer Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Prostate Cancer Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Prostate Cancer Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Use Of Hormonal Therapy In Early Treatment
  • 4.2.2 Increased Adoption Of Targeted Prostate Cancer Drugs
  • 4.2.3 Growing Focus On Castration-Resistant Prostate Cancer
  • 4.2.4 Expansion Of Combination Therapy Approaches
  • 4.2.5 Increased Hospital-Based Prostate Cancer Care

5. Prostate Cancer Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Urology Centers
• 5.4 Specialty Cancer Hospitals
• 5.5 Ambulatory Care Centers

6. Prostate Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Prostate Cancer Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Prostate Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Prostate Cancer Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Prostate Cancer Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Prostate Cancer Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Prostate Cancer Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Prostate Cancer Drugs Market Segmentation

• 9.1. Global Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer
• 9.2. Global Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy
• 9.3. Global Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Other End-Users
• 9.4. Global Prostate Cancer Drugs Market, Sub-Segmentation Of Hormone Sensitive Prostate Cancer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Early-Stage Prostate Cancer, Locally Advanced Prostate Cancer, Metastatic Prostate Cancer
• 9.5. Global Prostate Cancer Drugs Market, Sub-Segmentation Of Hormone Refractory Prostate Cancer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Castration-Resistant Prostate Cancer (CRPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)

10. Prostate Cancer Drugs Market Regional And Country Analysis

• 10.1. Global Prostate Cancer Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Prostate Cancer Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Prostate Cancer Drugs Market

• 11.1. Asia-Pacific Prostate Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Prostate Cancer Drugs Market

• 12.1. China Prostate Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Prostate Cancer Drugs Market

• 13.1. India Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Prostate Cancer Drugs Market

• 14.1. Japan Prostate Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Prostate Cancer Drugs Market

• 15.1. Australia Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Prostate Cancer Drugs Market

• 16.1. Indonesia Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Prostate Cancer Drugs Market

• 17.1. South Korea Prostate Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Prostate Cancer Drugs Market

• 18.1. Taiwan Prostate Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Prostate Cancer Drugs Market

• 19.1. South East Asia Prostate Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Prostate Cancer Drugs Market

• 20.1. Western Europe Prostate Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Prostate Cancer Drugs Market

• 21.1. UK Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Prostate Cancer Drugs Market

• 22.1. Germany Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Prostate Cancer Drugs Market

• 23.1. France Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Prostate Cancer Drugs Market

• 24.1. Italy Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Prostate Cancer Drugs Market

• 25.1. Spain Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Prostate Cancer Drugs Market

• 26.1. Eastern Europe Prostate Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Prostate Cancer Drugs Market

• 27.1. Russia Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Prostate Cancer Drugs Market

• 28.1. North America Prostate Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Prostate Cancer Drugs Market

• 29.1. USA Prostate Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Prostate Cancer Drugs Market

• 30.1. Canada Prostate Cancer Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Prostate Cancer Drugs Market

• 31.1. South America Prostate Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Prostate Cancer Drugs Market

• 32.1. Brazil Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Prostate Cancer Drugs Market

• 33.1. Middle East Prostate Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Prostate Cancer Drugs Market

• 34.1. Africa Prostate Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Prostate Cancer Drugs Market, Segmentation By Type, Segmentation By Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Prostate Cancer Drugs Market Regulatory and Investment Landscape

36. Prostate Cancer Drugs Market Competitive Landscape And Company Profiles

• 36.1. Prostate Cancer Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Prostate Cancer Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Prostate Cancer Drugs Market Company Profiles
  • 36.3.1. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

37. Prostate Cancer Drugs Market Other Major And Innovative Companies

• Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp.

38. Global Prostate Cancer Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Prostate Cancer Drugs Market

40. Prostate Cancer Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Prostate Cancer Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Prostate Cancer Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Prostate Cancer Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer